If you’re a woman of a certain age, your social media feed may be filled with claims that a single therapy will fight ...

The drug targets a specific mutation that applies to only 2% of ALS patients. A new drug may slow progression of -- and even reverse -- symptoms of a rare form of amyotrophic lateral sclerosis, or ALS ...

President Donald Trump has signed an executive order making some big changes to marijuana policy, the most substantial since 1970. On Dec. 18, Trump ordered the government to stop classifying ...

President Donald Trump signed an executive order Thursday reclassifying marijuana as a less dangerous drug — a move expected to ease restrictions so it's easier to purchase and sell, and pave the way ...

Aaron Navarro is a CBS News digital reporter. He covered the 2024 elections and was previously an associate producer for the CBS News political unit in the 2021 and 2022 election cycles. Washington — ...

The tablets are indicated for the treatment of moderate to severe vasomotor symptoms due to menopause. Dultra added, "We are proud to continue our mission of delivering high-quality, affordable ...

The federal government has announced the results of the latest round of Medicare drug price negotiations: 15 lower drug prices for Medicare to go into effect in 2027. Medicare will get a 71% discount ...

The U.S. has revealed price reductions for the second round of prescription drugs negotiated by the Centers for Medicare & Medicaid Services (CMS) through the Inflation Reduction Act (IRA). Headlining ...

(Reuters) -The U.S. Food and Drug Administration has initiated the removal of the agency's strictest "black box" warnings from hormone therapies given ‌to women to treat menopause symptoms, according ...

Health and Human Services Secretary Robert F. Kennedy Jr. announced Monday that the U.S. Food and Drug Administration would remove “broad black box” warnings from hormone replacement therapy products ...

– FDA removes black box warnings on menopause hormone therapies. – Two new treatments approved, including generic Premarin. – Move expands patient access and eases safety fears. WASHINGTON — The U.S.

GLP-1 drugs, originally developed for diabetes and obesity, may also curb addictive behaviors by acting on reward circuits in the brain. Early trials show reductions in alcohol intake, opioid seeking, ...